Search

I have axillary hyperhidrosis and have tried the temporary options but is there something permanent?

Updated: 5 days ago

According to an article in the Archives of Dermatological Research (1) , over 15 million people in the United States alone suffer from hyperhidrosis, or overactive/excessive sweating. Of those 15 million people, over half experience axillary hyperhidrosis or overactive underarm sweat. Hyperhidrosis can have very significant effects on patients’ lives, causing physical discomfort and social embarrassment and negatively impacting self-image as well as occupational and daily activities. Patients have told us stories of having to bring a change of clothes to social gatherings or to work due to sweating and avoiding certain colors or types of fabrics to mask the sweating.


For years those with axillary hyperhidrosis were limited to temporary treatment options such as prescription deodorant, wipes and as of 2004 the use of Botox injections to temporarily reduce underarm sweating. Not only are those treatments temporary but they can get expensive over time. Luckily for the 15 million Americans who suffer with this condition there is now a permanent and much more cost-effective option!


In 2011 miraDry received FDA approval to treat axillary hyperhidrosis and is now available in over 50 countries worldwide! miraDry is a device that uses thermal energy to permanently reduce underarm sweating by up to 82% in just a single one hour treatment. It is also cleared to remove underarm odor glands and up to 70% of underarm hair–– regardless of hair color! What patients love most is that their results are not only permanent but they are immediate. miraDry patients tell us that they feel a sense of freedom from embarrassment, from the restrictions of hyperhidrosis. Call Dr. Mary DuPont, hyperhidrosis and miraDry specialist of Chevy Chase, MD and Washington, DC and you can finally ditch those temporary fixes for good!

1. Doolittle, J., Walker, P., Mills, T. et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 308, 743–749 (2016). https://doi.org/10.1007/s00403-016-1697-9

1 view

Mary C. DuPont, MD, FACS

© 2020 by DuPont Institute, All Rights Reserved